• Dual-Action Inhibition of p38α: Modulating Kinase Dephosphor

  2026-06-12

  The referenced study reveals that certain p38 MAPK inhibitors not only block kinase activity but also accelerate p38α dephosphorylation by stabilizing a phosphatase-accessible conformation. This dual mechanism uncovers new avenues for improving specificity and efficacy in kinase-targeted research and therapy.

• CUDC-907: Dual PI3K and HDAC Inhibitor for In Vitro Workflow

  2026-06-12

  CUDC-907 enables controlled, simultaneous inhibition of class I PI3K and HDAC isoforms in cell-based cancer research models, supporting precise modulation of cell signaling, cell cycle arrest, and apoptosis assays. It is not validated for diagnostic or therapeutic applications and should be strictly limited to in vitro workflows.

• KX2-391 Dihydrochloride: Dual-Action Protocols in Oncology &

  2026-06-11

  KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) enables advanced experimental workflows targeting Src kinase, tubulin polymerization, HBV transcription, and botulinum neurotoxin A. Explore protocol-driven insights, troubleshooting strategies, and new directions based on the latest research and optimized for reproducibility across cancer, virology, and neurotoxin studies.

• AG-126 (Tyrphostin AG-126): Precision ERK Inhibition in Neur

  2026-06-11

  AG-126 (Tyrphostin AG-126) delivers targeted, reproducible inhibition of ERK1/2 for advanced in vitro and in vivo neural models. Its selectivity empowers mechanistic studies of neuroinflammation and repetitive behaviors, with workflow optimizations and troubleshooting strategies that streamline experimental success.

• Clodronate Liposomes: Precision In Vivo Macrophage Depletion

  2026-06-10

  Clodronate Liposomes enable rapid, tissue-specific in vivo macrophage depletion for dissecting immune function and resistance mechanisms in disease models. Their versatility across multiple administration routes and compatibility with advanced murine models make them indispensable for high-fidelity immune modulation studies.

• Phos binding reagent (Phosbind) acrylamide: SDS-PAGE Phospho

  2026-06-10

  Phos binding reagent (Phosbind) acrylamide enables SDS-PAGE-based detection of protein phosphorylation without phospho-specific antibodies, providing a practical workflow for researchers studying signal transduction and kinase activity. Best suited for differentiating phosphorylated from non-phosphorylated proteins in the 30–130 kDa range, it is not intended for applications outside this molecular weight window or for antibody-based detection workflows.

• SD 169 (indole-5-carboxamide): Mechanistic Advances in p38 M

  2026-06-09

  Explore how SD 169 (indole-5-carboxamide) enables next-generation selectivity and mechanistic control in inhibition of the p38 MAPK signaling pathway. This article delivers unique structural and functional insights for advanced type 1 diabetes and axonal regeneration research.

• TG003 and the Future of Splicing Modulation in Cancer Resist

  2026-06-09

  This article dissects the mechanistic and translational impact of TG003, a selective Cdc2-like kinase inhibitor, on alternative splicing and platinum resistance. Drawing on recent ovarian cancer research and practical workflow guidance, it provides strategic recommendations for researchers exploring splicing modulation as a therapeutic lever, while differentiating from conventional product summaries through integrative analysis and forward-looking insights.

• Neuroligin 1 Deletion in D2-MSNs Drives Repetitive ASD Behav

  2026-06-08

  This study reveals that loss of Neuroligin 1 in striatal D2 receptor-expressing medium spiny neurons leads to their hyperactivation, which is directly linked to increased repetitive behaviors characteristic of autism spectrum disorder. By elucidating the role of PKC overactivation in this process, the findings provide new mechanistic insight and suggest potential intervention points for core ASD symptoms.

• IPA-3 for Pak1 Autophosphorylation Inhibition: Applied Workf

  2026-06-08

  IPA-3 offers precision Pak1 autophosphorylation inhibition, enabling researchers to dissect kinase-driven signaling with high specificity across cancer and neuroinflammation models. This article details actionable workflows, practical troubleshooting, and how IPA-3 uniquely empowers in vitro and in vivo studies targeting Pak1, Pak2, and Pak3.

• Rotavirus Infection Suppresses Nrf2-Driven Redox Defense Pat

  2026-06-07

  This study reveals that progressive rotavirus infection leads to marked downregulation of the redox-sensitive transcription factor Nrf2 and its target genes, impairing the host cell’s antioxidant defense. These findings detail a mechanism by which rotavirus alters cellular stress responses and highlight vulnerabilities that may be therapeutically exploitable.

• Cell lysis buffer for WB and IP: Protease/Phosphatase Inhibi

  2026-06-06

  Cell lysis buffer for WB and IP enables rapid, non-denaturing protein extraction with broad-spectrum protease and phosphatase inhibitor cocktail protection. Its formulation preserves native protein complexes, supporting sensitive workflows like Western blot and immunoprecipitation. This article details the buffer's mechanistic advantages and limitations for researchers seeking robust protein degradation prevention.

• AG-490 (Tyrphostin B42): Unraveling Exosomal JAK2/STAT6 Modu

  2026-06-05

  Explore how AG-490 (Tyrphostin B42) enables advanced dissection of exosome-driven JAK2/STAT6 signaling in hepatocellular carcinoma. This in-depth guide reveals unique experimental and translational insights for immunopathological state suppression.

• Phos binding reagent (Phosbind) acrylamide for SDS-PAGE Phos

  2026-06-05

  Phos binding reagent (Phosbind) acrylamide enables antibody-free electrophoretic separation and detection of phosphorylated proteins during SDS-PAGE, streamlining protein phosphorylation analysis for research applications. It is optimal for proteins in the 30–130 kDa range and not recommended for long-term solution storage. This product is best suited for workflows requiring phosphorylation-dependent mobility shift detection without reliance on phospho-specific antibodies.

• Multi-Omics Uncovers ARID1A-Driven Resistance in Melanoma

  2026-06-04

  The reference study pioneers a multi-omics approach to delineate how ARID1A loss enables melanoma cells to resist BRAF/MAPK inhibitor therapy, mapping key adaptive and acquired resistance networks. These insights clarify the complex interplay between signaling rewiring and immune evasion, guiding future strategies to counteract therapy resistance in BRAF-mutant melanoma.

448 records 8/30 page Previous Next First page 上5页 678910 下5页 Last page